LEXINGTON, Mass., June 13, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage
LEXINGTON, Mass., June 13, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stagebiotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, announced they will host a conference call and webcast on Wednesday, June 14, 2017 at
The dial-in numbers are 1-877-870-4263 for domestic callers and 1-412-317-0790 for international callers. A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com.
After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.
About Aldeyra TherapeuticsAldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.
Corporate Contact:Stephen TulipanoAldeyra Therapeutics, Inc.Tel: +1 781-761-4904 ext. 205 [email protected]
Investor Contact:Chris BrinzeyWestwicke PartnersTel: 339-970-2843[email protected]
Media Contact:Cammy Duong MacDougall Biomedical Communications 781-591-3443[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-results-from-allergic-conjunctivitis-phase-2b-clinical-trial-300473316.html
SOURCE Aldeyra Therapeutics, Inc.
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...View All